
|Videos|February 13, 2017
Immune Targeting in Ovarian Cancer
Author(s)Maurie Markman, MD
Maurie Markman, MD, president of Medicine and Science, Eastern Regional Medical Center, discusses immune targeting in ovarian cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
3
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5



























